Press Releases

September 16, 2024
Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients

November 9, 2023
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

April 12, 2022
Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer

April 4, 2022
Trishula Therapeutics Announces Oral Presentation on TTX-030 Anti-CD39 Antibody at American Association for Cancer Research (AACR) Annual Meeting

January 21, 2021
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

August 26, 2020
Trishula Therapeutics Established to Advance Novel TTX-030, and Anti-CD39 Antibody, Being Evaluated in Phase 1/1B Study in Advanced Cancers